SOURCE: Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc. Logo

March 07, 2016 09:00 ET

Lion Biotechnologies to Participate in Upcoming Conferences

NEW YORK, NY--(Marketwired - March 07, 2016) - Lion Biotechnologies, (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that President and Chief Executive Officer, Elma Hawkins, PhD, will participate in the following upcoming conferences:

Cowen and Company 36th Annual Health Care Conference

Date: Wednesday, March 9, 2016

Location: Boston Marriott Copley Place, Boston, MA

Moffitt Cancer Center's Business of Biotech 2016

Date: Friday, March 18, 2016

Location: Moffitt Cancer Center, Tampa, FL

4th  Annual Cell & Gene Investor Day

Date: Tuesday, March 22, 2016

Location: Metropolitan Club, New York City

About Lion Biotechnologies

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.

Forward Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Investor Relations
    Molly Henderson 
    212.946.4826